Scaling up monitoring of risk minimization measures in women of childbearing age with anti-seizure medicines.

Kikuchi and colleagues must be commended for having investigated the temporal trends in prescribed anti-seizure medicines (ASMs) in Japanese women. [1] Indeed, ASMs’ teratogenicity has been by passed for too long: while first reports of valproate teratogenicity having been published in 1982, risk immunization measures were only issued in the mid 2010’s in Europe [2]. However, we are afraid that Kikuchi and colleagues’ report similarly illustrated how concerns for ASMs’ teratogenicity are not adequate in Japan yet.